Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma
File version
Author(s)
O'Leary, Nicole
Hamad, Nada
Cochrane, Tara
Ho, P Joy
Cheah, Chan Y
Bishop, David
Gregory, Gareth P
Butler, Jason
Barraclough, Allison
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Autologous CD19 chimeric antigen receptor T (CAR T)-cell therapies have significantly improved clinical outcomes for many patients with relapsed and refractory (R/R) lymphoma. However, the process of delivering CAR T-cell therapy is specialised and complex, in part due to specific post-infusion toxicities. Several CAR T-cell products are now available in Australia, although not all states have treatment centres. In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia. We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells.
Journal Title
Internal Medicine Journal
Conference Title
Book Title
Edition
Volume
55
Issue
S2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Persistent link to this record
Citation
Dickinson, M; O'Leary, N; Hamad, N; Cochrane, T; Ho, PJ; Cheah, CY; Bishop, D; Gregory, GP; Butler, J; Barraclough, A, Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma, Internal Medicine Journal, 2025, 55 (S2), pp. 4-27